Kuehne + Nagel provides healthcare logistics services for Roche in Chile
Kuehne + Nagel has been awarded an exclusive logistics contract to manage the warehousing and distribution activities for Roche Chile. Under the terms of the agreement, Kuehne + Nagel will handle end-products and raw materials. The services also cover the handling of sensitive cargo such as temperature-controlled biotechnological products and psychotropic medicines.
Kuehne + Nagel will support Roche Chile in optimizing its distribution processes, improving the performance of the 2,000 sqm logistics warehouse in Macul, Santiago, and will be responsible for the distribution to hospitals, clinics and pharmacy distribution centres throughout the country.
“Taking over last-mile delivery services for Roche in Chile is proof of the trust placed in us by a globally leading healthcare company and demonstrates our strong capacity to optimize processes and add value enabling the customer to focus on its core business,” commented Ingo Goldhammer, Managing Director of Kuehne + Nagel Chile. “We are committed to further developing and investing in our integrated solutions for the pharmaceutical and healthcare industry.”
René Delsin, General Manager of Roche Chile, said, “Roche is an innovative healthcare company, and this deal is part of our strategy to improve our focus on core activities locally. It will allow us to dedicate more attention to demand generation, without losing the quality of our current distribution in Chile. Working with Kuehne + Nagel, a world-class logistics service provider, we will also have the possibility to incorporate new technologies, explore synergies and further integrate our logistics and distribution processes, improving our efficiency and reducing inventories.”
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D.
The company has had operations in Chile for over 38 years. It employs around 250 people throughout the country.
Further information can be found at www.roche.com